2016-03-04T00:00:00.000-05:00
United States,0.223689
short life spans,-0.272236
Baxalta’s decision,-0.506344
clinical-stage biopharmaceutical company,0.310044
clinical trials,0.217232
Baxalta,0.0908042
future expectations,0.378162
clinical trial costs,0.451675
clinical development,0.503816
previous treatment,-0.338282
acute myeloid leukemia,-0.428158
cap.  Onconova,0.451675
novel products,0.310044
patient enrollment,-0.272236
myelodysplastic syndromes,-0.31924
additional clinical centers,-0.216381
MDS Centers,0.223689
INSPIRE trial,0.451675
rigosertib,-0.0312122
Onconova Therapeutics,0.310044
Onconova,-0.0577626
bone marrow disorders,-0.428158
pivotal trial,-0.272236
forward-looking statements,0.0316321
initial therapeutic focus,-0.31924
